Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Gefitinib with chemo ups survival in NSCLC regardless of EGFR mutation status

03 Sep 2017

Intercalating and maintenance gefitinib may improve progression-free survival (PFS) and overall survival (OS) in nonsmall cell lung cancer (NSCLC) patients with unknown epidermal growth factor receptor (EGFR) mutation status, a recent study has shown.

The investigators randomized 219 NSCLC patients who achieved stable disease after treatment with gemcitabine and carboplatin to either continue chemotherapy (n=110) or receive intercalating gefitinib with chemotherapy (n=109). Only those with unknown EGFR mutation status were included, while those with gefitinib allergies were excluded.

Major outcomes of the study were PFS, OS, tumour response and adverse events (AEs). Cox proportional hazards models were used to quantify the treatment effects.

Over a median follow-up of 20.5 months, patients in the gefitinib arm showed median PFS of 9.7 months. Compared with the control arm (median PFS, 4.2 months), PFS was significantly longer in the gefitinib arm (hazard ratio [HR], 95 percent CI, 0.41; 0.31 to 0.56; p<0.001).

Similarly, the median OS in the gefitinib arm (20.1 months) was significantly longer than in the control arm (15.4 months; HR, 0.68; 0.48 to 0.97; p=0.0323). There were 63 (57.8 percent) and 61 (55.5 percent) deaths in the gefitinib and control arms, respectively.

Eight weeks after randomization, only 19.3 percent (n=21) of the gefitinib group and 0.9 percent (n=1) of the control group achieved partial remission. No patient achieved complete response.

Moreover, stable disease was reported in 62.4 percent (n=68) of patients in the gefitinib group and 71.8 percent (n=79) of those in the control group. In contrast, 15.6 percent (n=17) and 19.1 percent (n=21) experienced disease progression in the gefitinib and control groups, respectively.

The objective response rate for the gefitinib and control groups were 19.3 and 0.9 percent, respectively, with the difference reaching statistical significance (p<0.0001).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
22 May 2017
Chronic obstructive pulmonary disease (COPD) is currently the 10th commonest cause of death in Singapore, with a disease burden of 5.9 percent according to a 2015 population-based survey (EPIC-Asia survey) in Singapore. Pearl Toh spoke with Dr Augustine Tee, chief and senior consultant of the Department of Respiratory and Critical Care Medicine at Changi General Hospital (CGH) in Singapore, on how COPD is often underdetected in the primary care population as symptoms are not specific and diagnosis requires a combination of clinical risk factors, symptoms and spirometry testing.
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.